Contents

Search

enfuvirtide (Fuzeon)

Indications: - HIV/AIDS (FDA-approved March 2003) Contraindications: - avoid during pregnancy (data insufficient) [4] Dosage: SC BID Adverse effects: 1) injection site reactions routine (painful skin nodules) 2) hypersensitivity (respiratory distress) 3) pneumonia Mechanism of action: 1) fusion inhibitor 2) prevents HIV from entering immune cells 3) addition of enfuvirtide to optimized anti-retoviral regimen results in significant declin in viral load Notes: cost $20,000/year (2003)

Interactions

drug interactions

General

viral fusion inhibitor; viral entry inhibitor

References

  1. Info: 866-694-6670
  2. Prescriber's Letter 10(4):23 2003
  3. Journal Watch 23(13):104-5, 2003 Lalezari P et al, NEJM 348(22):2175, 2003 Lazzarin A et al, NEJM 348(22):2175, 2003 Tshimi KT & Carpenter CCJ, NEJM 348(22):2249, 2003
  4. Zuger A Use of Antiretroviral Drugs in Pregnancy. Physician's First Watch, April 22, 2014 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org - Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 2014. AIDSinfo. Clinical Guidelines Portal. March 28, 2014. http://aidsinfo.nih.gov/Guidelines/HTML/3/perinatal-guidelines/0 (corresponding NGC guideline withdrawn March 2016)
  5. Department of Veterans Affairs, VA National Formulary